Five things for pharma marketers to know: Friday, May 26, 2017
1. FDA commissioner Scott Gottlieb presented policy plans aimed at addressing the prices of prescription drugs, including publishing lists of old drugs without generic competition. (WSJ)
2. Patients who are informed about the risks of a medication's side effects are more likely to report the symptoms than those who are unaware of them, according to a three-year study examining about 10,000 patients in the U.K., Ireland, and Scandinavia. (Reuters)
3. Scientists have published data about seizures, asthma attacks, and heart disease using Apple's Research Kit. They are now looking to use the technology to hack into mobile devices to see if they can become medical monitors. (Stat)
4. Novartis plans to cut 250 jobs in New Jersey, in an effort to consolidate its data unit in India. Last week, the drugmaker said it planned to cut 500 jobs in Basel and add 350 staff with technology experience. (Endpoints News)
5. Merck and Teijin Pharma entered a deal that gives Merck worldwide exclusive rights to develop and commercialize the Japanese drugmaker's experimental anti-tau antibody, a drug that is being tested as a treatment for Alzheimer's disease.